肿瘤相关性贫血的中西医研究进展

发布时间：2018-05-04 00:20

本文选题：癌症 + 贫血　；参考：《科技导报》2009年18期

【摘要】：贫血是肿瘤患者常见的并发症,其发生率及严重程度与性别、年龄、肿瘤类型、分期、化放疗等有关。贫血可引起组织缺氧,使患者生活质量降低,是影响肿瘤患者生活质量的重要因素。贫血程度与化疗疗效、化疗药物的敏感性及耐药性密切相关。贫血患者常规化疗预后较差。低血红蛋白可使肿瘤组织放疗敏感性降低,是放疗患者预后差的独立预后因素。肿瘤相关性贫血的病因是多样的,包括肿瘤自身因素、治疗因素及营养因素等。促红细胞生成素(EPO)的使用是治疗肿瘤相关性贫血的主要方法,可以有效提高患者的血红蛋白水平,改善肿瘤患者的生活质量,提高肿瘤化放疗的疗效。随着中医对肿瘤相关性贫血认识的不断深入,中医药在肿瘤相关性贫血的治疗中取得了良好的疗效。
[Abstract]:Anemia is a common complication in cancer patients. The incidence and severity of anemia are related to sex, age, tumor type, stage, chemoradiotherapy and so on. Anemia can lead to anoxia and decrease the quality of life, which is an important factor affecting the quality of life of tumor patients. The degree of anemia is closely related to the efficacy of chemotherapy, the sensitivity of chemotherapeutic drugs and drug resistance. The prognosis of anemia patients with conventional chemotherapy is poor. Low hemoglobin can reduce the sensitivity of tumor tissue to radiotherapy and is an independent prognostic factor for poor prognosis of patients with radiotherapy. The etiology of tumor-associated anemia is diverse, including tumor itself, treatment and nutrition. The use of erythropoietin (EPO) is the main method for the treatment of tumor-associated anemia, which can effectively improve the hemoglobin level of patients, improve the quality of life of tumor patients, and improve the curative effect of chemotherapy and radiotherapy. With the deepening understanding of tumor-related anemia in Chinese medicine, Chinese medicine has achieved a good effect in the treatment of tumor-related anemia.
【作者单位】：北京中医药大学基础医学院;中日友好医院中医肿瘤科;
【分类号】：R730.5

【参考文献】